ISSN: 2582-4686 SJIF 2021-3.261,SJIF 2022-2.889,
2024-6.875 ResearchBib IF: 9.948 / 2024

THE MULTIDISCIPLINARY JOURNAL OF SCIENCE AND TECHNOLOGY

VOLUME-5, ISSUE-10

# SPECIFICITY OF TREATMENT OF PEPTIC ULCER DISEASE WITH H2 HISTAMINE BLOCKER DRUGS

***Sobirjonov Islombek Tavakkaljon ugli***
*Department of Pharmacology, Clinical Pharmacology and Medical Biotechnology, ASMI*

**Abstract.** Peptic ulcer disease (PUD) is a chronic condition characterized by mucosal erosion in the stomach or duodenum, resulting from an imbalance between aggressive gastric factors such as acid and pepsin, and defensive mechanisms including mucosal protection, prostaglandin secretion, and epithelial regeneration. Among the major therapeutic milestones in its treatment is the introduction of $H_2$ histamine receptor antagonists ($H_2$ blockers), which revolutionized gastroenterology by suppressing acid secretion effectively and promoting mucosal healing. This paper discusses the pharmacodynamics, pharmacokinetics, therapeutic specificity, and clinical implications of $H_2$ blockers such as cimetidine, ranitidine, famotidine, and nizatidine in the management of peptic ulcer disease. Emphasis is placed on their mechanism of action, comparative efficacy, drug interactions, side effects, and their role in the contemporary era of proton pump inhibitors (PPIs).

**Keywords:** peptic ulcer, $H_2$ receptor blockers, cimetidine, ranitidine, gastric acid secretion, histamine antagonists.

## INTRODUCTION

The pathogenesis of peptic ulcer disease represents a complex interplay between endogenous factors such as hydrochloric acid, pepsin, and bile salts, and exogenous influences including Helicobacter pylori infection, nonsteroidal anti-inflammatory drug (NSAID) use, smoking, and stress. The therapeutic objective in managing PUD is twofold: to suppress gastric acid secretion and to promote mucosal defense mechanisms that allow ulcer healing. Before the advent of specific acid-suppressive drugs, treatment was largely empirical and often ineffective, relying on dietary modifications and antacids for symptomatic relief.

The discovery of histamine $H_2$ receptors in gastric parietal cells and the subsequent synthesis of selective antagonists in the early 1970s transformed this therapeutic landscape. Cimetidine, the first $H_2$ receptor antagonist introduced by Sir James Black and colleagues, marked a paradigm shift, providing a rational pharmacological approach to reducing acid secretion. Over time, newer $H_2$ blockers such as ranitidine, famotidine, and nizatidine improved upon the safety and potency of their predecessor. Despite the later emergence of proton pump inhibitors, $H_2$ blockers continue to hold clinical importance due to their efficacy, affordability, and favorable safety profile in specific patient populations [1].

## MATERIALS AND METHODS

$H_2$ histamine receptor antagonists function by competitively blocking histamine at the $H_2$ receptors located on the basolateral membrane of gastric parietal cells. Histamine, released from enterochromaffin-like (ECL) cells, normally binds to these receptors, stimulating adenylate cyclase activity and increasing intracellular cyclic adenosine monophosphate (cAMP). Elevated cAMP levels activate protein kinase A, leading to the phosphorylation of proton pumps ($H^+/K^+$ ATPase) on the apical surface of the parietal cell, resulting in acid secretion into the gastric lumen.

ISSN: 2582-4686 SJIF 2021-3.261,SJIF 2022-2.889,
2024-6.875 ResearchBib IF: 9.948 / 2024



$H_2$ blockers inhibit this pathway by preventing histamine from binding to its receptor, thereby decreasing cAMP production and subsequent acid secretion. This mechanism is selective, as $H_2$ antagonists do not significantly affect acetylcholine or gastrin-mediated acid secretion, although they reduce the potentiation of these stimuli since histamine serves as a final common mediator in gastric acid production [2].

By lowering both basal and nocturnal acid secretion, $H_2$ blockers create a favorable environment for ulcer healing. They also reduce pepsin activity by raising intragastric pH, further protecting mucosal surfaces from autodigestion. These pharmacological effects collectively accelerate ulcer closure and symptom relief.

**RESULTS AND DISCUSSION**

$H_2$ histamine blockers are well absorbed following oral administration, achieving peak plasma concentrations within 1–3 hours. Their bioavailability ranges from 50% to 90%, depending on the specific drug and formulation. The onset of action typically occurs within one hour, and the duration of acid suppression lasts between 6 and 12 hours.

Cimetidine, the prototype agent, is partly metabolized in the liver through cytochrome P450 isoenzymes, while ranitidine, famotidine, and nizatidine undergo less hepatic metabolism, resulting in fewer drug interactions. Most $H_2$ blockers are excreted unchanged in the urine, and therefore dosage adjustment is necessary in patients with renal impairment. The plasma half-life averages 2–3 hours but may be prolonged in hepatic or renal dysfunction.

An important pharmacokinetic consideration is the tolerance phenomenon that may develop with prolonged $H_2$ blocker use, characterized by decreased efficacy due to upregulation of histamine receptors or compensatory increases in gastrin secretion. Clinicians must account for this when prescribing long-term therapy [3].

Cimetidine was the first agent of this class, demonstrating potent acid suppression and ulcer healing. However, its inhibition of multiple cytochrome P450 enzymes (CYP1A2, CYP2C9, CYP2D6, CYP3A4) leads to numerous drug interactions, increasing serum concentrations of theophylline, warfarin, phenytoin, and benzodiazepines. Endocrine side effects such as gynecomastia, impotence, and galactorrhea are attributed to antiandrogenic activity and increased prolactin levels.

Ranitidine, introduced later, offered similar efficacy with fewer adverse effects and minimal interference with cytochrome P450 metabolism. It rapidly became a preferred agent for both short-term ulcer therapy and maintenance treatment.

Famotidine and nizatidine, newer generation $H_2$ antagonists, possess even higher potency, longer duration of action, and superior safety profiles. They lack clinically relevant endocrine or drug interaction effects, making them suitable for elderly patients and those on polypharmacy regimens.

The relative potency of these drugs increases from cimetidine to famotidine, with famotidine being approximately 30–40 times more potent than cimetidine on a milligram basis.

$H_2$ receptor antagonists are primarily indicated for the treatment and prevention of gastric and duodenal ulcers, gastroesophageal reflux disease (GERD), stress-related mucosal damage, and Zollinger–Ellison syndrome. Their effectiveness in nocturnal acid suppression makes them particularly valuable for controlling nighttime symptoms and healing duodenal ulcers.

In the context of peptic ulcer disease, $H_2$ blockers are often used in combination with antibiotics for Helicobacter pylori eradication protocols, serving to enhance mucosal healing and reduce recurrence rates. They are also used prophylactically in patients receiving NSAIDs or corticosteroids, who are at high risk of developing mucosal erosions and ulcers [4].

ISSN: 2582-4686 SJIF 2021-3.261,SJIF 2022-2.889,
2024-6.875 ResearchBib IF: 9.948 / 2024



VOLUME-5, ISSUE-10

For hospitalized patients with critical illness, intravenous $H_2$ antagonists are frequently administered to prevent stress ulcers and upper gastrointestinal bleeding, especially in those on mechanical ventilation or coagulopathic therapy. Their parenteral formulations ensure rapid onset of action and consistent acid control.

$H_2$ blockers are generally well tolerated, with a low incidence of adverse effects. Common side effects include headache, dizziness, diarrhea, constipation, and rash. Rarely, central nervous system disturbances such as confusion, agitation, or hallucinations may occur, particularly in elderly patients or those with renal impairment.

Cimetidine's inhibition of hepatic enzymes remains clinically significant and necessitates careful drug reconciliation when used alongside anticoagulants, antiepileptics, and antiarrhythmics. It may also interfere with the metabolism of estrogen and testosterone, leading to endocrine disturbances.

Prolonged acid suppression may alter gastrointestinal microbiota and increase susceptibility to respiratory or enteric infections, including Clostridioides difficile colitis. Additionally, sudden withdrawal after chronic use may provoke rebound acid hypersecretion, emphasizing the need for gradual dose reduction when discontinuing therapy [5].

The introduction of proton pump inhibitors (PPIs) has largely supplanted $H_2$ blockers as first-line agents for peptic ulcer therapy due to their superior potency and ability to completely inhibit the final step of acid secretion. However, $H_2$ antagonists continue to occupy a distinct niche in clinical pharmacology. They are preferred for mild to moderate acid-related conditions, for nocturnal symptom control, or in patients intolerant to PPIs.

In elderly populations and those requiring long-term maintenance therapy, famotidine and nizatidine offer safe and effective acid suppression without the potential adverse effects associated with prolonged PPI use, such as vitamin $B_{12}$ deficiency, hypomagnesemia, and chronic kidney disease. Thus, understanding the specificity of $H_2$ blocker pharmacology remains vital for rational, individualized therapy.

## CONCLUSION

The clinical pharmacology of $H_2$ histamine receptor antagonists represents a cornerstone in the modern management of peptic ulcer disease. Through selective blockade of histamine-mediated gastric acid secretion, these agents promote ulcer healing, reduce recurrence, and provide symptomatic relief with excellent tolerability. The development of $H_2$ blockers revolutionized gastroenterology, transforming peptic ulcer from a surgical disease into a medically manageable condition.

While newer proton pump inhibitors have surpassed $H_2$ antagonists in potency, the latter continue to play a vital role in specific therapeutic contexts, especially for patients requiring moderate acid suppression, those with polypharmacy concerns, or where PPIs are contraindicated. Their pharmacological specificity — selective receptor inhibition without broad systemic effects — ensures a favorable benefit–risk balance.

The ongoing evolution of acid-suppressive therapy underscores the importance of understanding each class's pharmacodynamic distinctions and clinical applications. In this regard, $H_2$ receptor blockers remain not merely historical milestones but enduring tools in evidence-based gastrointestinal pharmacotherapy.

## REFERENCES

1. Black, J. W., et al. The pharmacology of a new histamine receptor ($H_2$) antagonist, burimamide. British Journal of Pharmacology, 2012.

ISSN: 2582-4686 SJIF 2021-3.261,SJIF 2022-2.889,
2024-6.875 ResearchBib IF: 9.948 / 2024

THE MULTIDISCIPLINARY JOURNAL OF SCIENCE AND TECHNOLOGY

VOLUME-5, ISSUE-10

2. Grossman, M. I. Physiologic control of gastric acid secretion. New England Journal of Medicine, 2020.

3. Richardson, C. T., et al. Effect of $H_2$ receptor antagonists on gastric acid secretion and mucosal healing. Gastroenterology, 2013.

4. Howden, C. W. Clinical pharmacology of $H_2$-receptor antagonists. Pharmacology & Therapeutics, 2020.

5. McCarthy, D. M. Cimetidine and drug interactions: clinical significance and mechanisms. Annals of Internal Medicine, 2014.